Xiangyu Medical Co.,Ltd (SHA:688626)
China · Delayed Price · Currency is CNY 41.95
-0.10 (-0.24%)
Sep 30, 2026, 3:00 PM CST
Xiangyu Medical Co.,Ltd Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,547 | 9,442 | 4,574 | 8,375 | 5,028 | 9,107 | |
Market Cap Growth | -16.77% | 106.45% | -45.39% | 66.55% | -44.79% | - |
Enterprise Value | 6,234 | 9,261 | 4,193 | 7,553 | 3,711 | 7,670 |
Last Close Price | 41.95 | 60.28 | 29.10 | 51.90 | 30.88 | 54.51 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 77.65 | 120.81 | 44.43 | 36.87 | 40.08 | 45.11 |
Forward PE | 65.55 | 73.66 | 15.53 | 27.97 | 24.02 | 33.29 |
PS Ratio | 8.37 | 12.30 | 6.15 | 11.24 | 10.29 | 17.40 |
PB Ratio | 3.10 | 4.54 | 2.23 | 3.97 | 2.59 | 4.68 |
P/TBV Ratio | 3.48 | 5.09 | 2.51 | 4.45 | 2.92 | 5.28 |
P/FCF Ratio | - | - | - | - | - | 284.86 |
P/OCF Ratio | 36.26 | 49.74 | 25.61 | 36.75 | 26.93 | 54.90 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.97 | 12.06 | 5.64 | 10.14 | 7.60 | 14.65 |
EV/EBITDA Ratio | 67.44 | 107.12 | 39.19 | 36.22 | 53.22 | 49.96 |
EV/EBIT Ratio | 165.48 | 255.09 | 60.61 | 39.51 | 69.14 | 53.96 |
EV/FCF Ratio | - | - | - | - | - | 239.90 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.27 | 0.28 | 0.18 | 0.02 | 0.01 | - |
Debt / EBITDA Ratio | 6.22 | 6.41 | 3.36 | 0.17 | 0.25 | - |
Net Debt / Equity Ratio | -0.15 | -0.22 | -0.18 | -0.37 | -0.69 | -0.76 |
Net Debt / EBITDA Ratio | -3.63 | -5.20 | -3.52 | -3.79 | -19.30 | -9.63 |
Net Debt / FCF Ratio | 10.68 | 4.62 | 1.45 | 3.15 | 82.20 | -46.22 |
Asset Turnover | 0.24 | 0.25 | 0.27 | 0.30 | 0.22 | 0.33 |
Inventory Turnover | 0.88 | 0.98 | 1.05 | 1.05 | 0.89 | 1.17 |
Quick Ratio | 1.11 | 1.15 | 1.12 | 2.40 | 3.99 | 8.41 |
Current Ratio | 1.60 | 1.56 | 1.55 | 3.21 | 4.74 | 9.46 |
Return on Equity (ROE) | 3.99% | 3.67% | 4.94% | 11.28% | 6.35% | 14.84% |
Return on Assets (ROA) | 0.72% | 0.73% | 1.57% | 4.82% | 1.47% | 5.62% |
Return on Invested Capital (ROIC) | 2.01% | 2.20% | 4.43% | 18.72% | 9.37% | 32.91% |
Return on Capital Employed (ROCE) | 1.60% | 1.60% | 3.20% | 8.60% | 2.70% | 7.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.26% | 0.83% | 2.25% | 2.71% | 2.50% | 2.22% |
FCF Yield | -0.46% | -1.03% | -5.69% | -3.00% | -0.33% | 0.35% |
Dividend Yield | 0.43% | 0.30% | 0.83% | 1.02% | 0.78% | 0.70% |
Payout Ratio | 41.64% | 56.85% | 83.14% | 17.81% | 47.77% | 29.43% |
Buyback Yield / Dilution | 1.10% | 1.75% | 1.12% | 0.68% | -6.20% | -24.97% |
Total Shareholder Return | 1.53% | 2.05% | 1.94% | 1.70% | -5.42% | -24.27% |